Authors: | Patel, P. H.; Kondagunta, G. V.; Schwartz, L.; Ishill, N.; Bacik, J.; Deluca, J.; Russo, P.; Motzer, R. J. |
Article Title: | Phase II trial of lenalidomide in patients with metastatic renal cell carcinoma |
Abstract: | Lenalidomide (CC-5013) is a structural derivative of thalidomide, with antiangiogenic and immunomodulatory effects. Fourteen patients with metastatic renal cell carcinoma (RCC) were enrolled on a phase 2 trial of lenalidomide administered orally at 25 mg daily for 21 days followed by a rest period of 7 days. The best response was stable disease in eight patients (57%) of the 14 evaluable patients. Toxicities included fatigue, hyperglycemia, dyspnea, and myelosuppression with decreased hemoglobin, lymphopenia, and neutropenia. Lenalidomide is tolerable, but no objective responses were observed in this clinical trial. © 2007 Springer Science+Business Media, LLC. |
Keywords: | adult; cancer survival; clinical article; treatment outcome; aged; middle aged; lenalidomide; thalidomide; clinical trial; constipation; drug tolerability; fatigue; neutropenia; drug dose reduction; drug efficacy; hypertension; monotherapy; side effect; treatment duration; antineoplastic agents; cancer patient; metastasis; multiple cycle treatment; phase 2 clinical trial; anemia; bone marrow suppression; blood toxicity; dehydration; hemoglobin blood level; hypercalcemia; patient assessment; renal cell carcinoma; kidney carcinoma; kidney neoplasms; dyspnea; hyperglycemia; lymphocytopenia; carcinoma, renal cell; drug response; neoplasm metastasis; administration, oral; phase ii; cc-5013 |
Journal Title: | Investigational New Drugs |
Volume: | 26 |
Issue: | 3 |
ISSN: | 0167-6997 |
Publisher: | Springer |
Date Published: | 2008-06-01 |
Start Page: | 273 |
End Page: | 276 |
Language: | English |
DOI: | 10.1007/s10637-007-9107-y |
PUBMED: | 18161005 |
PROVIDER: | scopus |
DOI/URL: | |
Notes: | --- - "Cited By (since 1996): 6" - "Export Date: 17 November 2011" - "CODEN: INNDD" - "Source: Scopus" |